Enliven's Chief Scientific Officer Reduces Stake While Retaining 965K Shares

Rhea-AI Filing Summary

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, reported selling 12,500 shares of common stock on June 20, 2025, at a weighted average price of $21.3966 per share (ranging from $21.1228 to $22.0249), resulting in an approximate transaction value of $267,458.

Key details of the transaction:

• The sale was executed according to a Rule 10b5-1 trading plan established on November 15, 2024
• Following the transaction, Lyssikatos maintains indirect beneficial ownership of 965,188 shares through The Lyssikatos Revocable Trust 12/15/2011, where he serves as trustee
• The transaction was reported via Form 4 filing on June 24, 2025

Positive

• The insider sale was executed according to a pre-planned Rule 10b5-1 trading plan established in November 2024, indicating the transaction was not based on any new material information

Negative

• Chief Scientific Officer Joseph P. Lyssikatos sold 12,500 shares at an average price of $21.3966, reducing indirect beneficial ownership through The Lyssikatos Revocable Trust
• The sale represents a significant insider transaction, though the executive still maintains substantial holdings of 965,188 shares after the sale

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lyssikatos Joseph P

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF SCIENTIFIC OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/20/2025		S(1)		12,500	D	$21.3966(2)	965,188	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

2. This transaction was executed in multiple trades at prices ranging from $21.1228 to $22.0249. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

	/s/ Ben Hohl, by power of attorney	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares of IMRA did Joseph Lyssikatos sell on June 20, 2025?

According to the Form 4 filing, Joseph Lyssikatos, the Chief Scientific Officer, sold 12,500 shares of common stock on June 20, 2025 at a weighted average price of $21.3966 per share.

What was the price range of IMRA shares sold by Lyssikatos in this transaction?

The shares were sold in multiple trades with prices ranging from $21.1228 to $22.0249 per share, with a weighted average sale price of $21.3966.

How many IMRA shares does Joseph Lyssikatos still own after this sale?

Following the reported transaction, Lyssikatos beneficially owns 965,188 shares indirectly through The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee.

Was this IMRA insider sale part of a pre-planned trading arrangement?

Yes, the sales were executed pursuant to a Rule 10b5-1 trading plan that was adopted by Lyssikatos on November 15, 2024.

What is Joseph Lyssikatos's position at IMRA?

Joseph Lyssikatos serves as the Chief Scientific Officer of the company.